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Abstract
Objective
The long-term (5-year) outcome of early (3–6 weeks after acute myocardial infarction
[AMI], BM-MNC Early group) and late (3–4 months after AMI, BM-MNC Late group) com-
bined (percutaneous intramyocardial and intracoronary) delivery of autologous bone mar-
row mononuclear cells (BM-MNCs) was evaluated in patients with ejection fractions (EF)
between 30–45% post-AMI.
Methods
Major adverse cardiac and cerebrovascular events (MACCE) and hospitalization were
recorded. Left (LV) and right (RV) ventricular function were measured by transthoracic
echocardiography. Cardiac magnetic resonance imaging (MRI) and myocardial single pho-
ton emission computed tomography was performed in a subgroup of patients. Pre-cell ther-
apy myocardial voltage values of treated areas (assessed by NOGA mapping) were
correlated with clinical outcome.
Results
Five-year MACCE incidences (7.4%. vs 24.1%) and the composite of all adverse events
(11.1% vs 27.6%) were not different between the Early and Late treatment groups. The
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significant LV-EF increase at 1-year follow-up was preserved at the 5-year control (from
baseline to 5-year: 5.3%, 95% CI:0.5–10.1, and 5.7%, 95% CI:1.7–9.6, p<0.05 in the Early
and Late groups, respectively), with no significant changes between 1- and 5-year follow-
ups. Similarly, RVEF increased significantly from baseline to the 5-year follow-up (Early
group: 5.4%, 95% CI:1.0–9.6; and Late group: 8.4%, 95% CI:4.5–12.3). Lower baseline lev-
els of myocardial viability of the treated cardiac area (6.3±2.4 vs 8.2±3.0 mV, p<0.05) were
associated with incidence of MACCE.
Conclusions
Percutaneous combined delivery of autologous BM-MNCs is feasible and safe after 5
years, and may result in sustained improvement of cardiac function at 5 years in patients
with low EF post-AMI (Clinicaltrials.gov NCT01395212).
Introduction
Recent meta-analyses of randomized clinical studies including patients with acute myocardial
infarction (AMI) treated with/without intracoronary delivery of autologous bone marrow
(BM) mononuclear cells (MNC) introduced debate about the efficacy of this cardiac regenera-
tive treatment mode [1,2]. However, treatment of patients with chronic ischemic heart failure
receiving either intracoronary or intramyocardial delivery of cells of diverse type (BM-MNC,
autologous or allogeneic BM, or adipose tissue-derivedmesenchymal stem cells) seems to be
efficient in terms of significant increases in global left ventricular (LV) ejection fraction (EF) as
shown by recently published meta-analyses [3,4]. Intramyocardial injection of regenerative
cells has various advantages over intracoronary application such as negligible wash-out, with a
higher retention rate of the cells in the myocardium [5,6]. However, intracoronary delivery is
clinically more attractive because of its simplicity [7–9]. OurMYSTAR, prospective, single-
blind study included patients with recent AMI randomized to receive combined (intramyocar-
dial followed by intracoronary) autologous BM-MNCs injections early (3–6 weeks, BM-MNC
Early group) or late (3–4 months BM-MNC Late group) post-AMI with the aim of exploiting
the advantages of both deliverymodes [5]. The initial study was completed with a 1-year fol-
low-up in 2008 [5,10,11], demonstrating moderate but significant improvement in infarct size
and LV function [5].
Most cardiac regeneration studies report short-term (3–6 month) follow-up results while
somemid-term (over 1-year) follow-up studies suggested a possible loss of the initial benefits
of cardiac cell-based treatment [12]. Up to now, only few trials monitored patients who
received BM or peripheral blood-origin cell treatments for over 2 years. The BOOST (5 years),
ASTAMI (3 years), MAGIC (2 years), Cao study (4 years), MAGIC Cell3-DES (5 years),
REPAIR-AMI (2 years), TOPCARE-AMI (5 years), Plewka study (2 years) and the STIM stud-
ies reported heterogeneous long-term results (Table A in S1 File) [13–21].
Right ventricular (RV) dysfunction develops in approximately half of patients with MI in
the absence of posterior or inferior wall ischemia [22,23] and is attributed to multifactorial rea-
sons such as an increase in left atrial pressure and afterload, altered preload conditions, and RV
myocardial stunning. Several studies identified RV dysfunction as a strong prognostic factor
for in-hospital and mid- and long-termmortality, development of heart failure, and LV infarct
burden [22,23]. Currently, no data are available about the changes in RV function after cell-
therapy post AMI.
Five-Year Follow-Up of MYSTAR Study
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In this prospective study, we investigated the 5-year clinical outcome, LV and RV systolic
and LV diastolic function, and infarct size in patients included in the MYSTAR study. This is
the only trial that used the combined delivery route and investigated the long term effect of per-
cutaneous intramyocardial and intracoronary delivery of BM-MNCs on LV and RV function.
Methods
Study design
This is a single-center, 5-year follow-up study (MYSTAR-5-YEAR, clinicaltrials.gov
NCT01395212) including patients who participated in the MYSTAR trial at the Medical Uni-
versity of Vienna (clinicaltrials.govNCT00384982) (Fig 1) [5].
Patients
The MYSTAR study design, inclusion and exclusion criteria, primary and secondary end-
points, and 1-year results are published elsewhere [5,10]. Briefly, patients with a recent AMI
were included and randomized to Early (n = 30; BM-MNC therapy between 3 and 6 weeks) or
Late (n = 30; BM-MNC therapy between 3 and 4 months) groups receiving autologous
BM-MNC using combined delivery (intramyocardial followed by intracoronary) therapy a
mean ± standard deviation (SD) of 32 ± 12 or 93 ± 15 days post ST segment elevation myocar-
dial infarction (STEMI), respectively.
The main inclusion criteria were age>18 years, global LV EF between 30% and 45%, new
persistent local wall motion disturbance, no significant coronary artery lesion of more than
50% diameter stenosis, and written informed consent.
Fig 1. Study design.
doi:10.1371/journal.pone.0164908.g001
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The main exclusion criteria included previous heart surgery or AMI at the same location,
regional wall motion abnormality outside the index AMI area, and severe renal, lung, or liver
disease. Patients presenting with severe valve disease, hemoglobin level below 9 mg%, New
York Heart Association (NYHA) class IV, or ventricular thrombus were also excluded.
The detailed cell administration protocol was published previously. Briefly, after harvesting
of the BM and selecting the MNCs, patients in the Early and Late groups received 200.3±68.7
x106 and 194.8±60.4 x106 BM-MNCs intramyocardially followed by 1.3±0.68 x109 and 1.29
±0.41 x109 BM-MNCs intracoronary, respectively [5]. The locations of the percutaneous intra-
myocardial injections were guided by 3-dimensional NOGA endocardialmapping as described
previously [6]. The intracoronary infusions were given into the reopened infarct-related artery
at a slow injection rate [5].
All patients were invited to participate in the 5-year control investigations. The 5-year fol-
low-up study protocol was approved by the Ethik-Kommission der MedizinischenUniversität
Wien (EK Nr: 291/2011) and written informed consent was obtained from all study partici-
pants. The study was conducted according to the Declaration of Helsinki.
The patients underwent a series of 5-year follow-up tests including interviews (detailed
medical history and assessment of current medication and NYHA and Canadian Cardiovascu-
lar Society [CCS] classifications), physical assessment, routine clinical laboratory tests, electro-
cardiography, and transthoracic echocardiography. Cardiac magnetic resonance imaging
(MRI) and 99m-Sestamibi single photon emission computed tomography (SPECT) stress-rest
SPECT was performed in a subgroup of patients where applicable.
Study endpoints
The primary endpoint of the current follow-up study was the occurrence of major adverse car-
diac and cerebrovascular events (MACCE) including all-cause death, re-AMI, target vessel
revascularization (TVR), and stroke during the 5-year follow-up. Additionally, the incidence of
all adverse events (includingMACCE events, hospitalization and implantation of automatic
implantable cardioverter defibrillator (AICD) or pacemaker (PM) were listed.
The secondary endpoints were improvements in clinical symptoms expressed as CCS and
NYHA scores, changes in global LV- and RV-EF measured by echocardiography, size of the
infarction determined by stress-rest SPECT, LV and RV volumes, segmental wall motion, and
infarct transmurality and cardiac output measured by cardiac MRI.
Two-dimensional transthoracic echocardiography (TTE)
Patients underwent a conventional TTE (Vivid 7, General Electric Inc), with acquisition of the
apical chamber view in accordance with the current guidelines [24]. The left and right atrial
and LV and RV end-diastolic diameters were measured. LV- and RV-EF were calculated with
the biplane Simpson’s method from the 4- and 2-chamber views. LV wall motion score index
(WMSI) was calculated according to updated guidelines. Diastolic LV functionwas docu-
mented by measuring the peak E- and A-wave velocities and the isovolumetric relaxation time
by pulsed Doppler imaging.
At the 5-year follow-up, additional tissue Doppler imaging was performed using the apical
four-chamber view. The peak early diastolic (e0) velocities were measured in the lateral and sep-
tal mitral annulus by calculating the mean values. Tricuspid annular plane systolic excursions
(TAPSE) of the baseline, 1-year, and 5-year follow-up images were also measured from the
4-chamber view usingM-mode, with the position of the cursor on the lateral tricuspid annulus.
Structural abnormalities, such as myocardial calcification,were searched [25].
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Gated 99m-Technetium Sestamibi SPECT
A 2-day stress/rest (500–700MBq 99mTc-Sestamibi) SPECT protocol was performed using
dipyridamole infusion over 4–6 min (0.57 mg/kg/min by infusion pump) for the pharmacolog-
ical stress study. The stress tests at inclusion and at follow-ups were performedwith identical
tracers, exercise loads, and cumulative dipyridamole doses. Infarct size was measured by quan-
tifying the extent of tracer defect.
Cardiac MRI
The MRI studies were performed on a 1.5-T, cardiac-dedicated, clinical magnetic resonance
system (Sonata/Avanto, SiemensMedical Solutions, Erlangen, Germany). For the functional
studies, 3 standard long-axis slices and a stack of contiguous short-axis slices (slice thickness:
10 mm, no gap, 30 phases/RR-interval) were acquired with electrocardiography-gated, steady-
state, free-precession cine-images (repetition time 2.9 ms, echo time 1.2 ms, flip angle 80°,
matrix 256×146, field of view typically 340 mm, band width 930 Hz/pixel) using a breath-hold
technique. The late gadolinium enhancement (LE) images covering the LV were acquired 10
min after intravenous injection of 0.2 mM/kg gadolinium-diethyltriamine-penta-acetic acid
(Magnevist, Bayer Schering Pharma, Germany) with a segmented inversion recovery sequence
and inversion time optimized to null normal myocardial signal (TI between 200 ms and 300
ms). The LE images were acquired at end-systole and in the same position as the functional
studies. For quantification of LV and RV function and volumes, the endocardial and epicardial
contours were tracedmanually in end-systole and -diastole with dedicated software. The LV
mass was calculated from the total myocardial volume multiplied by the specific gravity of the
myocardium (1.05 g/ml). LE was defined as myocardial areas with signal intensity above the
average of apparently normal myocardium plus 2 standard deviations using a 17-segment
model, and expressed as a percentage of LV. The segmental analysis was carried out using
Medviso Segment software in which the AHA 17-segment model was visually aligned and reg-
istered to the segmented LV myocardium. The segmental contraction velocity of the LV myo-
cardium at the time point of peak ejection (cm/s) and the segmental infarct transmurality
(line-based approach %) was calculated.
Analyses of the NOGA® endocardial mapping and NOGA-guided
myocardial SPECT
The myocardial viability expressed as unipolar voltage values (UPV), segmental wall motion
(local linear shortening [LLS]) expressed as percentage, and infarct transmurality expressed as
bipolar voltage values (BiP) were determined by NOGA endocardial mapping of the injected
area [11,26].
Statistics
All analyses were performed by an independent observer blinded to the randomization groups
and time of the investigations. Continuous parameters are expressed as mean±standard devia-
tion (SD); categorical variables are expressed as percentages. Descriptive statistics were used to
describe the primary and secondary endpoints. The incidences of MACCE and all adverse
events and continuous parameters were compared between the Early and Late groups; these
were analyzed by chi-square and unpaired T-test, respectively. Baseline and follow-up data
within the group were compared using ANOVA with repeated measurements supplemented
by paired t-test. To analyze the effects of potential prognostic factors on the changes in the
infarct size and in global EF at the 5-year follow-up (dependent variables) after excluding
Five-Year Follow-Up of MYSTAR Study
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possible confounding factors, multivariate linear regression analysis was performed including
the following independent variables: age, number of intra-myocardial and intra-coronary
injected BM-MNCs, baseline values of UPV, LV EDV, and EF. Diabetes mellitus, male gender,
randomization group (early or late) was correlated with MACCE using nominal logistic regres-
sion analysis.
For all tests, two-sided analyses were used and the significance level was set at p<0.05. The
statistical analysis was carried out with SPSS1 software for the Mac OS 10 operating system.
Results
Patients
Baseline characteristics for the entire patient population have been published previously [5,11].
The mean age of the patients at the 5-year follow-up was 57.5±9.1 years.
Four patients refused the follow-up investigations (all were symptom-free); therefore, the
5-year clinical follow-up was available for 56 (93.3%) patients. Five patients died during the
5-year follow-up; thus 51 patients completed the LV functional study.
Primary Endpoint Results
The frequency of adverse events is listed in Table 1.
One patient received PM due to tachycardia-bradycardia syndrome. Four of the 56 patients
participating in the 5-year investigation (7.1%) received AICD; 2 with progressive heart failure
and malignant arrhythmias and 2 with low EF (baseline35%) and ischemic cardiomyopathy
for primary prevention of sudden cardiac death.
MACCE occurred in 9 of 56 patients (16.1%). Overall, 12 (21.4%) patients experienced
adverse events. Some patients experiencedmultiple events such as implantation of AICD
and TVR; in such cases, the most serious event was graded for the adverse event. The inci-
dence of MACCE and the combined adverse events was not different between the Early and
Late groups.
Table 1. Primary end point: occurrence of adverse events during the 5-year follow-up. In patients with multiple events during the 5-year FUP, the
most serious major adverse event was entered as MACCE and the composite of all adverse events (one/patient) for each patient.
Adverse events during 5-year follow-
up
Patients with 5-year follow-
up (n = 56)
Patients with 5-year follow-up Early
group (n = 27)
Patients with 5-year follow-up Late
group (n = 29)
Adverse events
PM/AICD implantation 5 (8.9%) 2 (7.4%) 3 (10.3%)
Hospitalization due to angina pectoris or
heart failure
9 (16.1%) 3 (11.1%) 6 (20.7%)
MACCE events (one/patient)
TVR 4 (7.1%) 1 (3.7%) 3 (10.3%)
Re-AMI 0 (0%) 0 0
Stroke 0 (0%) 0 0
All cause death 5 (8.9%) 1 (3.7%) 4 (13.8%)
Composite MACCE 9 (16.1%) 2 (7.4%) 7 (24.1%)
Composite of all adverse events
(one/patient)
12 (21.4%) 3 (11.1%) 8 (27.6%)
PM: pacemaker. AICD: automatic implantable cardioverter defibrillator, TVR: target vessel revascularization; AMI: acute myocardial infarction; MACCE:
major adverse cardiac and cerebrovascular events.
doi:10.1371/journal.pone.0164908.t001
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Secondary Endpoint Results
The increase in global LV-EF and decrease in infarct size one year after cell therapy was pre-
servedduring the 5-year follow-up. In the entire group, the mean increase in LV-EF between
pre-BM-MNC therapy and the 5-year follow-up was 5.4% (95% CI 2.3, 8.5; p<0.05) while this
value between 1-year and 5-year follow-up was 1.9% (95% CI 1.4, 5.3; p = non-significant). The
mean increase in LV-EF did not differ between the Early and Late groups, with both groups
showing perceived improvement between pre-cell therapy and the 5-year follow-up (5.3%, 95%
CI: 0.5, 10.1; p<0.05 in the Early group and 5.7%, 95% CI: 1.7, 9.6; p<0.05 in the Late group),
while no changes between 1- and 5-year follow-up were seen in either group. However, due to
lack of placebo control group, the observedLV and RV functional improvement can not be
completely attributed to the cell therapy.
Similarly, theWMSI improved from baseline to the 1-year follow-up, and was preserved at
the 5-year follow-up (Table 2) in both groups.
The changes in LV function and infarct size pre-cell therapy, at 1 and 5-years FUP are dis-
played in Fig 2.
Trends towards decrease in LA and LV end-diastolic diameter were recorded. The mean
increase in RV-EF in all patients was 3.2% (95% CI 2.0, 4.4; p<0.05) between baseline and the
1-year follow-up and 6.2% (95% CI 4.6, 7.8; p<0.05) between baseline and the 5-year follow-
up, with no difference between the Early and Late groups (mean increase in EF from baseline
to 5-year follow-up was 5.4%, 95% CI 1.0, 9.6; and 8.4%, 95% CI 4.5, 12.3, respectively).
A trend towards an increase in E/A (p<0.1) was measured at the 1-year follow-up with no
further change during the next follow-ups regarding all diastolic function parameters. The
peak early diastolic velocity (e`) was 6.1±1.5 cm/s resulting in an E/e`ratio of 13.4±4.9. No dif-
ference between groups was detected at the 5-year follow-up.
Echocardiography did not show any myocardial calcification or tumor formation attribut-
able to cardiac cell-based therapy [27].
In association with a decrease in the N-terminal pro-BNP level, NYHA classification
improved significantly at the 5-year follow-up, while the Canadian Cardiovascular Society clas-
sification did not change (Table 2), with no difference between the groups.
Subgroup analyses
SPECT imaging showed a mean decrease in infarct size of 6.9% (95% CI −2.2, −11.7, p<0.01)
between pre-BM-MNC therapy and the 5-year follow-up, and 3.8% (95% CI −9.0, 1.3;
p = non-significant) between the 1- and 5-year post-BM-MNC therapy (Table 3), with no dif-
ference between the Early and Late groups.
Fig 3 displays the serial gated scintigraphy pictures of a patient treated with combined deliv-
ery of autologous BM-MNCs.
No stress-inducedmyocardial ischemia was detected during the 5-year investigations.
Similar to echocardiography, cardiac MRI showed a preserved improvement in LV-EF at 5
years when compared to baseline values, with a trend towards a decrease in LV end-diastolic
and end-systolic volumes and increase in LV cardiac output (Table 3). RV-EF increased signifi-
cantly 1-year post BM-MNC therapy, with preserved improvement during the 5-year follow-
up. Since echocardiography did not show a difference between the Early and Late groups
regarding LV and RV function at the 5-year follow-up, the groups were not compared in the
subpopulation of patients available for myocardial perfusion scintigraphy or cardiac MRI.
MRI with late enhancement revealed a significant decrease in infarct mass (Table 3), with a
significant increase in segmental contractility (Table B in S1 File) and decrease in segmental
Five-Year Follow-Up of MYSTAR Study
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infarct transmurality (Table 4) in 3 of the 17 myocardial segments (anteroseptal, anteroapical,
and apex) (Fig 4).
Table 2. Secondary end points of patients with LV functional studies (n = 51) 5 years after cardiac bone-marrow mononuclear cell (BM-MNC)
therapy.
Before BM-MNC therapyAll patients
(n = 51) (Early vs Late group)
1 year post BM-MNC therapy All patients
(n = 51) (Early vs Late group)
5 years follow-up All patients
(n = 51) (Early vs Late group)
Transthoracic
echocardiography
LA diameter (mm) 53.6±8.9 48.3±7.8 47.1±7.7
52.2±9.2 vs 55.0±8.4 47.6±8.2 vs 49.0±7.6 45.3±10.0 vs 48.9±4.5
LV EDD (mm) 54.3±7.0 51.9±7.3 53.1±8.6
54.5±5.7 vs 54.0±8.2 51.2±52.6 vs 52.6±7.4 51.8±7.3 vs 54.0±9.4
RA diameter (mm) 51.9±6.3 54.0±6.9 53.7±6.4
51.3±7.3 vs 52.6±5.1 53.2±6.7 vs 54.6±7.2 52.6±5.6 vs 54.5±6.9
RV EDD (mm) 32.7±5.1 32.6±3.7 32.7±4.5
32.0±4.8 vs 33.4±5.3 32.1±5.4 vs 32.9±4.8 33.7±2.8 vs 32.2±5.2
LV EF (%) 39.2±9.3 41.5±8.3 a 44.8±10.3 b
39.7±8.8 vs 38.7±7.7 42.7±10.5 vs 42.1±7.4 45.0±9.3 vs 44.3±6.9
LV WMSI 1.82±0.46 1.68±0.43 1.53±0.73 b
1.81±0.57 vs 1.84±0.39 1.65±0.40 vs 1.70±0.46 1.59±0.74 vs 1.50±0.73
RV EF (%) 42.3±7.1 45.5±8.3 a 49.1±8.3 b
43.1±6.9 vs 41.4±7.2 46.5±9.2 vs 44.5±7.3 48.5±9.4 vs 49.8±7.2
Peak E velocity (m/s) 0.74±0.20 0.80±0.21 0.77±0.21
0.75±0.22 vs 0.73±0.18 0.79±0.12 vs 0.81±0.2 0.76±0.22 vs 0.78±0.2
Peak A velocity (m/s) 0.83±0.15 0.80±0.15 0.81±0.13
0.80±0.14 vs 0.86±0.16 0.77±0.12 vs 0.84±0.16 0.80±0.12 vs 0.82±0.14
E/A ratio 0.93±0.32 1.0±0.35 0.98±0.32
0.97±0.15 vs 0.88±0.28 1.07±0.37 vs 1.0±0.33 0.99±0.35 vs 0.97±0.29
Isovolumetric relaxation
time (ms)
99±9 96±8 100±10
98±9 vs 99±10 94±8 vs 98±7 99±10 vs 102±11
E/e‘ratio not measured not measured 13.4±4.9
12.2±4.2 vs 14.5±5.3
TAPSE (cm) 13.2±4.2 15.2±4.2 15.6±4.1
13.5±2.4 vs 12–7±4.8 15.5±6.4 vs 14.5±3.8 15.5±6.4 vs 15.0±3.8
Clinical symptoms
NYHA 2.0±1.0 1.4±0.7 1.3±0.6 b
2.0±1.0 vs 2.1±0.9 1.5±0.7 vs 1.3±0.7 1.4±0.6 vs 1.3±0.6
CCS 1.2±0.7 1.2±0.5 0.9±1.0
0.7±0.9 vs 1.7±0.9 1.2±0.6 vs 1.2±0.5 1.0±1.0 vs 0.8±0.9
Pro-BNP (pg/ml) 1323±1249 956±1057 465±537 b
1762±1732 vs 1031±742 1220±1439 vs 786±732 311±212 vs 578±670
ap<0.05: before BM-MNC therapy vs. 1 year post BM-MNC treatment
bp<0.05: before BM-MNC therapy vs. 5 years follow-up.
LA: diameter of left atrium; RA: diameter of the right atrium; LV: left ventricular; RV: right ventricular; EDD: end-diastolic diameter; EF: ejection fraction;
WMSI: wall motion score index; TAPSE: tricuspid annular plane systolic excursion; NYHA: New York Heart Association of Heart Failure; CCS: Canadian
Cardiovascular Society grading of angina pectoris.
doi:10.1371/journal.pone.0164908.t002
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Fig 2. Left ventricular function and infarct size of patients randomized to Early or Late cell-therapy during the 5-year follow-up. Patients were
treated with combined delivery of autologous BM-MNC. Global left ventricular (LV) ejection fraction, wall motion score index (measured by
echocardiography), and infarct size (by single photon emission computed tomography) of patients in the Early and Late groups before receiving cardiac
BMMNCs therapy and 1 and 5 years post cell therapy. No differences between the Early and Late group were observed.
doi:10.1371/journal.pone.0164908.g002
Table 3. Left and right ventricular function in subgroup of patients. underwent single photon emission computed tomography (SPECT) and cardiac
magnetic resonance imaging (cMRI) 5 years after cardiac bone-marrow mononuclear cell (BM-MNC) therapy.
Before BM-MNC therapy 1-year post BM-MNC therapy 5-year follow-up
SPECT (n = 31)
Infarct size (%) 27.4±10.7 24.3±11.6 20.1±11.8 b
cMRI (n = 26)
LV EDV (ml) 209±52.3 192.1±41.3 188.3±44.9
LV ESV (ml) 123.8±38.6 105.9±32.5 101.9±36.1
LV SV (ml) 85.2±19.9 86.1±15.4 86.3±16.2
LV EF (%) 41.4±6.5 45.7±7.2 a 47.0±8.1 b
Late enhancement (%) 25.0±16.9 20.9±14.4 18.0±12.6
LV CO (L/min) 5.0±1.3 5.2±1.2 5.6±1.2 b
LV mass (g) 204±57 196±44 183±50
Infarct mass (g) 49±40 42±28 33±326 b
RV EDV (ml) 159.2±32.0 150.3±19.7 146.9±21.3
RV ESV (ml) 87.7±34.7 72.5±18.1 66.4±12.6
RV SV (ml) 71.5±12.3 77.8±11.0 80.4±14.9
RV EF (%) 46.4±5.0 52.3±7.4 a 54.8±6.0 b
RV CO (L/min) 4.2±0.7 4.6±0.9 5.4±1.1 b
a p<0.05: before BM-MNC therapy vs. 1 year post BM-MNC treatment
b p<0.05: before BM-MNC therapy vs. 5 years follow-up.
LV: left ventricular; RV: right ventricular; EDV: end-diastolic volume. ESV: end-systolic volume. SV: stroke volume; EF: ejection fraction. CO: cardiac output.
doi:10.1371/journal.pone.0164908.t003
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Multivariate linear regression analysis did not reveal prognostic factors of improvement in
infarct size (measured in a subgroup of patients) or global EF. In contrast with the 3-month fol-
low-up results, no correlation could be found between the number of injected BM-MNC and
changes in infarct size in this subgroup of patients after 5 years.
Nominal logistic regression analysis could not identify predictive factors for occurrence of
MACCE, all adverse events, or mortality. However, patients with 5-year MACCE in both
groups had significantly lower baseline UPV values in the intramyocardially injected areas (6.3
±2.4 vs 8.2±3.0 mV, p<0.05) (Fig 4).
Discussion
This is the first prospective 5-year follow-up study of cell-based cardiac therapy delivered by
percutaneous intramyocardial BM-MNC delivery followed by intracoronary cell injections.
Our study demonstrated preserved global LV-EF, local wall motion abnormality, infarct size,
and RV-EF. Trends towards decreased LV end-diastolic and end-systolic volumes, and LV
Fig 3. Gated 99m-Sestamibi myocardial scintigraphy of a patient with cardiac bone marrow mononuclear cell (BM-MNC) treatment. (A) and (B)
Before combined cardiac delivery of autologous BM-MNC treatment; 3-dimensional calculation of LV volume (A) and polar map of infarct size (B). (C) and
(D) At the 1-year follow-up, 3-dimensional calculation of LV volume (C) and polar map for infarct size (D). (E) and (F) At the 5-year follow-up, 3-dimensional
calculation of LV volume (E) and polar map for infarct size (F).
doi:10.1371/journal.pone.0164908.g003
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end-diastolic and LA diameter were also shown, suggesting reverse remodeling post-AMI. To
the best of our knowledge, this is the first study highlighting improved RV function and the
long-term prognostic importance of the NOGA-derived parameter as higher baseline UPV was
associated with event-free survival during the 5-year follow-up.
Comparison of the follow-up results with other cardiac cell-based
studies
Table A in S1 File summarizes the main and controversial results of published long-term fol-
low-up of percutaneous cardiac cell-based treatment studies [13–21]. According to the obvious
differencies between the trials regarding the applied cell types and deliverymodes, duration of
follow-up, and timing of treatment post-AMI, a direct comparison between studies is not feasi-
ble. To note, no long-term follow-up results are currently available in a randomized intramyo-
cardial injection study that also included a placebo arm with which we could compare our
study. Therefore, a direct association between intra-myocardial (or combined) cell therapy and
persistent improvement in LV and RV function cannot be definitively concluded. Additionally,
the strong and consequent clinical control of patients with guidelines-drivenmedicinal ther-
apy, as well as revascularizationmight also have contributed to the supposed preserved benefit
of the cell therapy and must be kept in mind. Unfortunately, not all patients could be controlled
at the long-term follow-up, and five patients who initially had worse LV and RV function died;
these facts might also influence the final results.
However, considering that the first 3-month follow-up in the Early group showed signifi-
cantly better LV functionwhen compared with the Late group, who were still on medical treat-
ment 3 months post randomization, and the improvement in LV function and infarct size in
the Late group after cell-based therapy, we could assume at least an indirect association
between clinical improvement in patients treated with combined delivery of autologous
BM-MNCs [5].
Table 4. Segmental infarct transmurality determined by cardiac magnetic resonance imaging (n = 26).
Segment location Before BM-MNC therapy 1 year post BM-MNC therapy 5 years follow-up
Basal anterior [%] 4.6±13.4 10.9±13.7 0.0±0.0
Basal anteroseptal [%] 4.6±12.0 11.1±13.1 0.4±1.4
Basal inferoseptal [%] 2.4±6.0 9.5±10.9 0.8±2.5
Basal inferior [%] 3.0±7.4 10.2±11.3 0.0±0.0
Basal inferolateral [%] 3.4±8.7 10.8±11.8 0.0±0.0
Basal anterolateral [%] 5.8±14.0 12.0±13.6 0.0±0.0
Mid anterior [%] 30.2±30.8 25.4±23.4 26.5±7.8
Mid anteroseptal [%] 46.2±32.7 37.4±28.8 31.4±26.7
Mid inferoseptal [%] 17.6±16.1 18.6±12.9 15.8±26.6
Mid inferior [%] 3.8±9.0 10.2±11.1 0.2±0.7
Mid inferolateral [%] 4.0±9.7 10.0±11.1 0.0±0.0
Mid anterolateral [%] 12.3±27.3 15.0±22.1 10.0±0.0
Apical anterior [%] 60.6±28.9 66.9±27.0 32.1±17.2 a
Apical septal [%] 81.8±13.4 72.8±11.8 69.2±12.9 a
Apical inferior [%] 23.4±16.4 21.3±13.3 26.4±21.0
Apical lateral [%] 6.5±15.1 10.5±13.1 0.9±2.1
Apex [%] 61.8±23.5 44.5±30.3 41.5±20.2 a
a p<0.05 betwwen baseline (before BM-MNC therapy) and 5-year follow-up values.
doi:10.1371/journal.pone.0164908.t004
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The results of a very recent meta-analysis that included trials with intracoronary delivery of
BM-MNCs or mixed cell types raised questions about the efficacy of this therapy in patients
with recent STEMI [1,2]. Our patient collective and study design differs substantially from
those trials as the MYSTAR study included the earliest patients at 3 weeks (Early group) and
up to 4 months (Late group) post-AMI and used combined cell delivery. Previously, we sup-
posed that the intramyocardial cell delivery was responsible for the observedbenefit [11].
Unfortunately, not all patients could be controlled at the long-term follow-up, and five
patients who initially had worse LV and RV function died; these facts might also influence the
final results.
As the AICD implantation frequency for primary prevention in ischemic cardiomyopathy
ranges between 17–31%, and the incidence of malignant arrhythmias was low in our patient
population, it is unlikely that the intramyocardial injections of BM-MNCwere directly related
to malignant cardiac arrhythmias [28]. Considering, that a 37-month mortality rate of 25.6%
was reported in patients with LV EF between 36–45%, the total 8.3%mortality rate of our
patients with baseline EF between 30–45% post-AMImight be considered as low, and the
study safe [29].
Fig 4. Schematic display of the segmental transmurality and NOGA electromechanical mapping-derived parameter. (A) Schematic display of the
segmental transmurality using MathLab software, showing a decrease in infarct transmurality over 5 years in patients with acute myocardial infarction who
were treated with combined delivery of cells. Summed data from 26 patients. (B) NOGA electromechanical mapping-derived parameter in patients with or
without major adverse events during the 5-year follow-up. *p<0.05.
doi:10.1371/journal.pone.0164908.g004
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We measured LV and RV function by transthoracic echocardiography as this functional
investigation was available for all patients. Due to AICD or other implants, cardiac MRI could
only be performed in a smaller group of patients (n = 26), while 31 patients underwent stress-
rest SPECT. Recently, it was pointed out that the negative long-term outcome studies
(ASTAMI, BOOST) used cardiac MRI to assess cardiac function [13,14]. In contrast, the posi-
tive outcome studies measured LV functionwith quantitative left ventriculography or echocar-
diography, methods that carry the bias of missing explicit objectivity. We also used
transthoracic echocardiography; however, the LV-EF and its changes measured by MRI in a
subgroup of patients were similar to that of the echocardiographymeasurements in the entire
controlled patient cohort, even though patients with AICD due to low LV-EF were excluded
from the MRI investigations.
To our knowledge, this is the first study demonstrating the improvement of RV function in
patients with AMI and treated with cardiac cell-based therapy. The underlyingmechanism
might be the decreased afterload as a consequence of restoration of LV function, narrowing the
gap between LV and RV cardiac output. Additionally, the improvement in the infarct size and
local wall motion of the septal part of the anterior (96% of patients in the MRI subgroup) or
inferior infarction might influence RV function.
A trend towards minor improvements in diastolic dysfunctionwas recorded 1-year post cell
therapy; however, a clinically relevant robust change in diastolic functionwas not expected in
patients with an initial LV-EF between 30% and 45%. However, our data are similar to those of
the published diastolic dysfunction in other cell-therapy trials [14].
The decrease in heart failure parameters such as NT-proBNP or NYHA classification is an
indicator of improvement in the patients’ clinical status. This might be due to treatment with
medication to treat heart failure, with a consequent decrease inWMSC and increase in LVEF.
According to the study design, all patients were treated with BM-MNCs; thus, we cannot deter-
mine whether the decrease in heart failure parameters can be attributed to the cell therapy.
Subgroup analyses
CardiacMRI in a subgroup of patients showed a significant reduction in the infarct mass from
baseline to the 5-year follow-up, with a trend towards decreases in total LV mass, probably due to
decreases in LV EDV, suggesting reverse remodeling. Parallel to decreases in infarct transmurality,
the segmental contractility improved in 3/17 myocardial segments, supporting the echocardio-
graphic data of the entire patient population. A trend towards decreased infarct size measured by
myocardial scintigraphy and decreased infarct mass by cardiacMRI was observedat the 1-year
follow-up. The LV EF decreased significantly at both the 1- and 5-year follow-up whenmeasured
by both echocardiography andMRI. Since the EF not only depends on the infarct size and mass,
but also the geometryof the LV and adverse remodeling, the resting myocardial function
expressed as EF is not necessarily directly associatedwith the morphological size of the infarction.
Subanalysis revealed significantly lower baseline UPV values of the intramyocardially
injected area in patients experiencingMACCE. BecauseUPV is an index of myocardial viabil-
ity, this finding is in accordance with previous statements on the predictability of myocardial
viability on mortality measured by SPECT [26,30].
Higher numbers of cells (>108) delivered intracoronary were reported to be in association
with better long-term outcomes [31]. Higher numbers of intramyocardially injected cells pre-
dicted significant improvement in the infarct size at the 3-month follow-up [5]. Obviously, the
initial impact of the cell number on cardiac function disappeared during the long-term follow-
up. Of note, the infarct size determined by SPECT could be measured in a subgroup of the
patients (n = 31) at the 5-year follow-up.
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Limitations
Patients in the MYSTAR study were randomized to Early and Late groups based on the princi-
ple that patients in the Late group were still on pharmacological treatment when the patients in
the Early group were controlled 3-month post cardiac BM-MNC treatment. However, patients
in the Late group were also treated 93±15 days post-AMI. The lack of a placebo group is a
major limitation of our study; however, intramyocardial injection with a placebo substance
raised ethical considerations in patients with recent AMI. Arbitrary selection of a control
group from the 785 patients screened between 2002 and 2006 might have resulted in a severe
bias in the study interpretation.
Although the number of our BM-MNC-treated patients is similar to that of the cell-treated
arm of the randomized ASTAMI and TOPCARE-AMI, our study was underpowered regarding
adverse events. However, according to a recently published statistical power calculation of
myocardial regenerative studies, over 5000 participants should be included in each randomized
group in order to detect any significant changes in mortality rates due to the reportedminimal
long-term incidence of death in patients treated with cardiac BM-MNCs [31].
Conclusions
Percutaneous combined (intramyocardial and intracoronary) administration of autologous
BM-MNCs is feasible and safe after 5 years, and may result in sustained improvement of car-
diac function at 5 years in patients with low EF post-AMI. Higher initial voltage values in the
cell injection area were associated with a lower long-term adverse event rate, which highlights
the prognostic value of the myocardial viability factor derived from the electroanatomical
mapping.
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